29 results on '"Basu, Reetobrata"'
Search Results
2. Structure and function of a dual antagonist of the human growth hormone and prolactin receptors with site-specific PEG conjugates
- Author
-
Basu, Reetobrata, Brody, Rich, Sandbhor, Uday, Kulkarni, Prateek, Davis, Emily, Swegan, Deborah, Caggiano, Lydia J., Brenya, Edward, Neggers, Sebastian, and Kopchick, John J.
- Published
- 2023
- Full Text
- View/download PDF
3. Covert actions of growth hormone: fibrosis, cardiovascular diseases and cancer
- Author
-
Kopchick, John J., Basu, Reetobrata, Berryman, Darlene E., Jorgensen, Jens O. L., Johannsson, Gudmundur, and Puri, Vishwajeet
- Published
- 2022
- Full Text
- View/download PDF
4. Growth hormone modulates Trypanosoma cruzi infection in vitro
- Author
-
Mora-Criollo, Patricia, Basu, Reetobrata, Qian, Yanrong, Costales, Jaime A., Guevara-Aguirre, Jaime, Grijalva, Mario J., and Kopchick, John J.
- Published
- 2022
- Full Text
- View/download PDF
5. Mice with gene alterations in the GH and IGF family
- Author
-
Qian, Yanrong, Berryman, Darlene E., Basu, Reetobrata, List, Edward O., Okada, Shigeru, Young, Jonathan A., Jensen, Elizabeth A., Bell, Stephen R. C., Kulkarni, Prateek, Duran-Ortiz, Silvana, Mora-Criollo, Patricia, Mathes, Samuel C., Brittain, Alison L., Buchman, Mat, Davis, Emily, Funk, Kevin R., Bogart, Jolie, Ibarra, Diego, Mendez-Gibson, Isaac, Slyby, Julie, Terry, Joseph, and Kopchick, John J.
- Published
- 2022
- Full Text
- View/download PDF
6. Growth Hormone Upregulates Melanoma Drug Resistance and Migration via Melanoma-Derived Exosomes.
- Author
-
Kulkarni, Prateek, Basu, Reetobrata, Bonn, Taylor, Low, Beckham, Mazurek, Nathaniel, and Kopchick, John J.
- Subjects
- *
PROTEIN metabolism , *MELANOMA , *SKIN tumors , *DRUG resistance in cancer cells , *PHENOMENOLOGICAL biology , *RESEARCH funding , *ANTINEOPLASTIC agents , *CELL motility , *BIOCHEMISTRY , *DESCRIPTIVE statistics , *CANCER chemotherapy , *ONCOLOGY nursing , *CELL culture , *CELL lines , *METASTASIS , *PROTEOLYTIC enzymes , *DOXORUBICIN , *HUMAN growth hormone , *EXOSOMES - Abstract
Simple Summary: Melanoma, a severe type of skin cancer, often becomes resistant to chemotherapy, making it difficult to treat. This research investigates a novel mechanism by which growth hormone (GH) contributes to chemotherapy resistance. We examined small particles, called exosomes, which are released from melanoma cells treated with GH and found to carry proteins that increase drug resistance and cancer cell movement. The effects were more pronounced when GH was combined with the chemotherapy drug, doxorubicin. We also found that blocking the GH action with a drug called pegvisomant reduced the expression of these exosomal proteins, ultimately making the cancer cells more responsive to chemotherapy and less likely to migrate. Our findings provide new insights into how GH action promotes melanoma chemoresistance via exosomes, suggesting that targeting/inhibiting GH action could improve melanoma treatment. Drug resistance in melanoma is a major hindrance in cancer therapy. Growth hormone (GH) plays a pivotal role in contributing to the resistance to chemotherapy. Knocking down or blocking the GH receptor has been shown to sensitize the tumor cells to chemotherapy. Extensive studies have demonstrated that exosomes, a subset of extracellular vesicles, play an important role in drug resistance by transferring key factors to sensitize cancer cells to chemotherapy. In this study, we explore how GH modulates exosomal cargoes from melanoma cells and their role in drug resistance. We treated the melanoma cells with GH, doxorubicin, and the GHR antagonist, pegvisomant, and analyzed the exosomes released. Additionally, we administered these exosomes to the recipient cells. The GH-treated melanoma cells released exosomes with elevated levels of ABC transporters (ABCC1 and ABCB1), N-cadherin, and MMP2, enhancing drug resistance and migration in the recipient cells. GHR antagonism reduced these exosomal levels, restoring drug sensitivity and attenuating migration. Overall, our findings highlight a novel role of GH in modulating exosomal cargoes that drive chemoresistance and metastasis in melanoma. This understanding provides insights into the mechanisms of GH in melanoma chemoresistance and suggests GHR antagonism as a potential therapy to overcome chemoresistance in melanoma treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Growth Hormone Receptor Antagonist Markedly Improves Gemcitabine Response in a Mouse Xenograft Model of Human Pancreatic Cancer.
- Author
-
Basu, Reetobrata, Kulkarni, Prateek, Swegan, Deborah, Duran-Ortiz, Silvana, Ahmad, Arshad, Caggiano, Lydia J., Davis, Emily, Walsh, Christopher, Brenya, Edward, Koshal, Adeel, Brody, Rich, Sandbhor, Uday, Neggers, Sebastian J. C. M. M., and Kopchick, John J.
- Subjects
- *
SOMATOTROPIN receptors , *PITUITARY dwarfism , *HORMONE antagonists , *PANCREATIC cancer , *TREATMENT effectiveness , *LABORATORY mice , *GEMCITABINE - Abstract
Chemotherapy treatment against pancreatic ductal adenocarcinoma (PDAC) is thwarted by tumoral activation of multiple therapy resistance pathways. The growth hormone (GH)–GH receptor (GHR) pair is a covert driver of multimodal therapy resistance in cancer and is overexpressed in PDAC tumors, yet the therapeutic potential of targeting the same has not been explored. Here, we report that GHR expression is a negative prognostic factor in patients with PDAC. Combinations of gemcitabine with different GHR antagonists (GHRAs) markedly improve therapeutic outcomes in nude mice xenografts. Employing cultured cells, mouse xenografts, and analyses of the human PDAC transcriptome, we identified that attenuation of the multidrug transporter and epithelial-to-mesenchymal transition programs in the tumors underlie the observed augmentation of chemotherapy efficacy by GHRAs. Moreover, in human PDAC patients, GHR expression strongly correlates with a gene signature of tumor promotion and immune evasion, which corroborate with that in syngeneic tumors in wild-type vs. GH transgenic mice. Overall, we found that GH action in PDAC promoted a therapy-refractory gene signature in vivo, which can be effectively attenuated by GHR antagonism. Our results collectively present a proof of concept toward considering GHR antagonists to improve chemotherapeutic outcomes in the highly chemoresistant PDAC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Extending lifespan by modulating the growth hormone/insulin-like growth factor-1 axis: coming of age
- Author
-
Duran-Ortiz, Silvana, List, Edward O., Basu, Reetobrata, and Kopchick, John J.
- Published
- 2021
- Full Text
- View/download PDF
9. Mouse models of growth hormone deficiency
- Author
-
List, Edward O., Basu, Reetobrata, Duran-Ortiz, Silvana, Krejsa, Jackson, and Jensen, Elizabeth A.
- Published
- 2021
- Full Text
- View/download PDF
10. GH and IGF1 in cancer therapy resistance.
- Author
-
Basu, Reetobrata and Kopchick, John J.
- Subjects
- *
SOMATOMEDIN C , *CANCER treatment , *SOMATOTROPIN , *GROWTH factors - Abstract
Despite landmark advances in cancer treatments over the last 20 years, cancer remains the second highest cause of death worldwide, much ascribed to intrinsic and acquired resistance to the available therapeutic options. In this review, we address this impending issue, by focusing the spotlight on the rapidly emerging role of growth hormone action mediated by two intimately related tumoral growth factors -- growth hormone (GH) and insulin-like growth factor 1 (IGF1). Here, we not only catalog the scientific evidences relating specifically to cancer therapy resistance inflicted by GH and IGF1 but also discuss the pitfalls, merits, outstanding questions and the future need of exploiting GH--IGF1 inhibition to tackle cancer treatment successfully. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
11. High growth hormone serum partially protects mice against Trypanosoma cruzi infection.
- Author
-
Mora‐Criollo, Patricia, Basu, Reetobrata, Qian, Yanrong, Funk, Kevin, Bell, Stephen, Young, Jonathan A., List, Edward O., Costales, Jaime A., Guevara‐Aguirre, Jaime, Grijalva, Mario J., and Kopchick, John J.
- Subjects
SOMATOTROPIN ,TRYPANOSOMA cruzi ,TRANSGENIC mice ,SOMATOTROPIN receptors ,CHAGAS' disease ,PARASITIC diseases ,INSULIN receptors - Abstract
Chagas disease (CD) is one of the most devasting parasitic diseases in the Americas, affecting 7–8 million people worldwide. In vitro and in vivo experiments have demonstrated that growth hormone (GH) serum levels decrease as CD progresses. Interestingly, inactivating mutations in the GH receptor in humans result in Laron syndrome (LS), a clinical entity characterized by increased serum levels of GH and decreased insulin growth factor‐1 (IGF‐1). The largest cohort of LS subjects lives in the southern provinces of Ecuador. Remarkably, no clinical CD cases have been reported in these individuals despite living in highly endemic areas. In the current ex vivo study, we employed serum from GHR−/− mice, also known as LS mice (a model of GH resistance with high GH and low IGF‐1 levels), and serum from bovine GH (bGH) transgenic mice (high GH and IGF‐1), to test the effect on Trypanosoma cruzi infection. We infected mouse fibroblast L‐cells with T. cruzi (etiological CD infectious agent) and treated them with serum from each mouse type. Treatment with GHR−/− serum (LS mice) significantly decreased L‐cell infection by 28% compared with 48% from control wild‐type mouse serum (WT). Treatment with bGH mouse serum significantly decreased infection of cells by 41% compared with 54% from WT controls. Our results suggest that high GH and low IGF‐1 in blood circulation, as typically seen in LS individuals, confer partial protection against T. cruzi infection. This study is the first to report decreased T. cruzi infection using serum collected from two modified mouse lines with altered GH action (GHR−/− and bGH). [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
12. Promotion of Joint Degeneration and Chondrocyte Metabolic Dysfunction by Excessive Growth Hormone in Mice.
- Author
-
Zhu, Shouan, Liu, Huanhuan, Davis, Trent, Willis, Craig R. G., Basu, Reetobrata, Witzigreuter, Luke, Bell, Stephen, Szewczyk, Nathaniel, Lotz, Martin K., Hill, Marcheta, Fajardo, Roberto J., O'Connor, Patrick M., Berryman, Darlene E., and Kopchick, John J.
- Subjects
ALANINE metabolism ,TRYPTOPHAN metabolism ,LYSINE metabolism ,KNEE joint ,CARTILAGE cells ,KNEE osteoarthritis ,SYNOVITIS ,ANIMAL experimentation ,METABOLOMICS ,RISK assessment ,CYTOCHEMISTRY ,GENE expression ,RESEARCH funding ,ARTICULAR cartilage ,PITUITARY hormones ,COMPUTED tomography ,OXIDOREDUCTASES ,MICE ,OXIDATION-reduction reaction ,FATTY acids ,DISEASE risk factors - Abstract
Objective: Many patients with acromegaly, a hormonal disorder with excessive growth hormone (GH) production, report pain in joints. We undertook this study to characterize the joint pathology of mice with overexpression of bovine GH (bGH) or a GH receptor antagonist (GHa) and to investigate the effect of GH on regulation of chondrocyte cellular metabolism. Methods: Knee joints from mice overexpressing bGH or GHa and wild‐type (WT) control mice were examined using histology and micro–computed tomography for osteoarthritic (OA) pathologies. Additionally, cartilage from bGH mice was used for metabolomics analysis. Mouse primary chondrocytes from bGH and WT mice, with or without pegvisomant treatment, were used for quantitative polymerase chain reaction and Seahorse respirometry analyses. Results: Both male and female bGH mice at ~13 months of age had increased knee joint degeneration, which was characterized by loss of cartilage structure, expansion of hypertrophic chondrocytes, synovitis, and subchondral plate thinning. The joint pathologies were also demonstrated by significantly higher Osteoarthritis Research Society International and Mankin scores in bGH mice compared to WT control mice. Metabolomics analysis revealed changes in a wide range of metabolic pathways in bGH mice, including beta‐alanine metabolism, tryptophan metabolism, lysine degradation, and ascorbate and aldarate metabolism. Also, bGH chondrocytes up‐regulated fatty acid oxidation and increased expression of Col10a. Joints of GHa mice were remarkably protected from developing age‐associated joint degeneration, with smooth articular joint surface. Conclusion: This study showed that an excessive amount of GH promotes joint degeneration in mice, which was associated with chondrocyte metabolic dysfunction and hypertrophic changes, whereas antagonizing GH action through a GHa protects mice from OA development. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
13. Assays, Surrogates, and Alternative Technologies for a TB Lead Identification Program Targeting DNA Gyrase ATPase
- Author
-
Humnabadkar, Vaishali, Madhavapeddi, Prashanti, Basavarajappa, Halesha, Sheikh, Md. Gulebahar, Rane, Rajendra, Basu, Reetobrata, Verma, Prateek, Sundaram, Aishwarya, Mukherjee, Kakoli, and de Sousa, Sunita M.
- Published
- 2015
- Full Text
- View/download PDF
14. Growth Hormone Receptor Knockdown Sensitizes Human Melanoma Cells to Chemotherapy by Attenuating Expression of ABC Drug Efflux Pumps
- Author
-
Basu, Reetobrata, Baumgaertel, Nicholas, Wu, Shiyong, and Kopchick, John J.
- Published
- 2017
- Full Text
- View/download PDF
15. Growth Hormone and the Epithelial-to-Mesenchymal Transition
- Author
-
Brittain, Alison L, Basu, Reetobrata, Qian, Yanrong, and Kopchick, John J
- Published
- 2017
16. Increased Fibrosis in White Adipose Tissue of Male and Female bGH Transgenic Mice Appears Independent of TGF-β Action.
- Author
-
Bell, Stephen, Young, Jonathan A, List, Edward O, Basu, Reetobrata, Geitgey, Delaney K, Lach, Grace, Lee, Kevin, Swegan, Deborah, Caggiano, Lydia J, Okada, Shigeru, Kopchick, John J, and Berryman, Darlene E
- Subjects
FIBROSIS ,TRANSGENIC mice ,ADIPOSE tissues - Abstract
Fibrosis is a pathological state caused by excess deposition of extracellular matrix proteins in a tissue. Male bovine growth hormone (bGH) transgenic mice experience metabolic dysfunction with a marked decrease in lifespan and with increased fibrosis in several tissues including white adipose tissue (WAT), which is more pronounced in the subcutaneous (Sc) depot. The current study expanded on these initial findings to evaluate WAT fibrosis in female bGH mice and the role of transforming growth factor (TGF)-β in the development of WAT fibrosis. Our findings established that female bGH mice, like males, experience a depot-dependent increase in WAT fibrosis, and bGH mice of both sexes have elevated circulating levels of several markers of collagen turnover. Using various methods, TGF-β signaling was found unchanged or decreased—as opposed to an expected increase—despite the marked fibrosis in WAT of bGH mice. However, acute GH treatments in vivo, in vitro, or ex vivo did elicit a modest increase in TGF-β signaling in some experimental systems. Finally, single nucleus RNA sequencing confirmed no perturbation in TGF-β or its receptor gene expression in any WAT cell subpopulations of Sc bGH WAT; however, a striking increase in B lymphocyte infiltration in bGH WAT was observed. Overall, these data suggest that bGH WAT fibrosis is independent of the action of TGF-β and reveals an intriguing shift in immune cells in bGH WAT that should be further explored considering the increasing importance of B cell–mediated WAT fibrosis and pathology. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
17. Growth hormone receptor antagonism downregulates ATP-binding cassette transporters contributing to improved drug efficacy against melanoma and hepatocarcinoma in vivo.
- Author
-
Basu, Reetobrata, Yanrong Qian, Mathes, Samuel, Terry, Joseph, Arnett, Nathan, Riddell, Trent, Stevens, Austin, Funk, Kevin, Bell, Stephen, Bokal, Zac, Batten, Courtney, Smith, Cole, Mendez-Gibson, Isaac, Duran-Ortiz, Silvana, Lach, Grace, Mora-Criollo, Patricia Alexandra, Kulkarni, Prateek, Davis, Emily, Teaford, Elizabeth, and Berryman, Darlene E.
- Subjects
SOMATOTROPIN receptors ,ATP-binding cassette transporters ,SOMATOTROPIN ,DRUG efficacy ,DRUG resistance in cancer cells ,MELANOMA ,TRANSGENIC mice - Abstract
Knockdown of GH receptor (GHR) in melanoma cells in vitro downregulates ATP-binding cassette-containing (ABC) transporters and sensitizes them to anti-cancer drug treatments. Here we aimed to determine whether a GHR antagonist (GHRA) could control cancer growth by sensitizing tumors to therapy through downregulation of ABC transporters in vivo. We intradermally inoculated Fluc-B16-F10 mouse melanoma cells into GHA mice, transgenic for a GHR antagonist (GHRA), and observed a marked reduction in tumor size, mass and tumoral GH signaling. Moreover, constitutive GHRA production in the transgenic mice significantly improved the response to cisplatin treatment by suppressing expression of multiple ABC transporters and sensitizing the tumors to the drug. We confirmed that presence of a GHRA and not a mere absence of GH is essential for this chemo-sensitizing effect using Fluc-B16-F10 allografts in GH knockout (GHKO) mice, where tumor growth was reduced relative to that in GHsufficient controls but did not sensitize the tumor to cisplatin. We extended our investigation to hepatocellular carcinoma (HCC) using human HCC cells in vitro and a syngeneic mouse model of HCC with Hepa1-6 allografts in GHA mice. Gene expression analyses and drug-efflux assays confirm that blocking GH significantly suppresses the levels of ABC transporters and improves the efficacy of sorafenib towards almost complete tumor clearance. Human patient data for melanoma and HCC show that GHR RNA levels correlate with ABC transporter expression. Collectively, our results validate in vivo that combination of a GHRA with currently available anti-cancer therapies can be effective in attacking cancer drug resistance. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
18. Growth hormone receptor gene disruption in mature‐adult mice improves male insulin sensitivity and extends female lifespan.
- Author
-
Duran‐Ortiz, Silvana, List, Edward O., Ikeno, Yuji, Young, Jonathan, Basu, Reetobrata, Bell, Stephen, McHugh, Todd, Funk, Kevin, Mathes, Samuel, Qian, Yanrong, Kulkarni, Prateek, Yakar, Shoshana, Berryman, Darlene E., and Kopchick, John J.
- Subjects
SOMATOTROPIN ,INSULIN sensitivity ,SOMATOTROPIN receptors ,LABORATORY mice ,LEAN body mass ,MICE ,BODY size - Abstract
Studies in multiple species indicate that reducing growth hormone (GH) action enhances healthy lifespan. In fact, GH receptor knockout (GHRKO) mice hold the Methuselah prize for the world's longest‐lived laboratory mouse. We previously demonstrated that GHR ablation starting at puberty (1.5 months), improved insulin sensitivity and female lifespan but results in markedly reduced body size. In this study, we investigated the effects of GHR disruption in mature‐adult mice at 6 months old (6mGHRKO). These mice exhibited GH resistance (reduced IGF‐1 and elevated GH serum levels), increased body adiposity, reduced lean mass, and minimal effects on body length. Importantly, 6mGHRKO males have enhanced insulin sensitivity and reduced neoplasms while females exhibited increased median and maximal lifespan. Furthermore, fasting glucose and oxidative damage was reduced in females compared to males irrespective of Ghr deletion. Overall, disrupted GH action in adult mice resulted in sexual dimorphic effects suggesting that GH reduction at older ages may have gerotherapeutic effects. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
19. A novel peptide antagonist of the human growth hormone receptor.
- Author
-
Basu, Reetobrata, Nahar, Khairun, Kulkarni, Prateek, Kerekes, Olivia, Sattler, Maya, Hall, Zachary, Neggers, Sebastian, Holub, Justin M., and Kopchick, John J.
- Subjects
- *
HUMAN growth hormone , *SOMATOTROPIN , *GROWTH disorders , *PHOSPHORYLATION , *METABOLIC disorders , *AMINO acids , *SOMATOTROPIN receptors - Abstract
Excess circulating human growth hormone (hGH) in vivo is linked to metabolic and growth disorders such as cancer, diabetes, and acromegaly. Consequently, there is considerable interest in developing antagonists of hGH action. Here, we present the design, synthesis, and characterization of a 16-residue peptide (site 1-binding helix [S1H]) that inhibits hGH-mediated STAT5 phosphorylation in cultured cells. S1H was designed as a direct sequence mimetic of the site 1 minihelix (residues 36-51) of wild-type hGH and acts by inhibiting the interaction of hGH with the human growth hormone receptor (hGHR). In vitro studies indicated that S1H is stable in human serum and can adopt an a-helix in solution. Our results also show that S1H mitigates phosphorylation of STAT5 in cells co-treated with hGH, reducing intracellular STAT5 phosphorylation levels to those observed in untreated controls. Furthermore, S1H was found to attenuate the activity of the hGHR and the human prolactin receptor, suggesting that this peptide acts as an antagonist of both lactogenic and somatotrophic hGH actions. Finally, we used alanine scanning to determine how discrete amino acids within the S1H sequence contribute to its structural organization and biological activity. We observed a strong correlation between helical propensity and inhibitory effect, indicating that S1H-mediated antagonism of the hGHR is largely dependent on the ability for S1H to adopt an a-helix. Taken together, these results show that S1H not only acts as a novel peptide-based antagonist of the hGHR but can also be applied as a chemical tool to study the molecular nature of hGH-hGHR interactions. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
20. Differential gene signature in adipose tissue depots of growth hormone transgenic mice.
- Author
-
Duran‐Ortiz, Silvana, Young, Jonathan A., Jara, Adam, Jensen, Elizabeth A., Basu, Reetobrata, List, Edward O., Qian, Yanrong, Kopchick, John J., and Berryman, Darlene E.
- Subjects
SOMATOTROPIN ,TRANSGENIC mice ,ADIPOSE tissues ,RNA sequencing ,FATTY acid oxidation ,GENE ontology - Abstract
Bovine growth hormone (bGH) transgenic mice mimic the clinical condition of acromegaly, having high circulating growth hormone (GH) levels. These mice are giant, have decreased adipose tissue (AT) mass, impaired glucose metabolism and a shortened lifespan. The detrimental effects of excess GH have been suggested, in part, to be a result of its depot‐specific actions on AT. To investigate this relationship, we evaluated gene expression, biological mechanisms, cellular pathways and predicted microRNA (miRNA) in two AT depots (subcutaneous [Subq] and epididymal [Epi]) from bGH and littermate controls using RNA sequencing analysis. Two analyses on the differentially expressed genes (DEG) were performed: (i) comparison of the same AT depot between bGH and wild‐type (WT) mice (genotype comparison) and (ii) comparison of Subq and Epi AT depots within the same genotype (depot comparison). For the genotype comparison, we found a higher number of significant DEG in the Subq AT depot of bGH mice compared to WT controls, corroborating previous reports that GH has a greater impact on the Subq depot. Furthermore, most of the DEG in bGH mice were not shared by WT mice, suggesting that excess GH induces the expression of genes not commonly present in AT. Through gene ontology and pathway analysis, the genotype comparison revealed that the DEG of the Subq depot of bGH mice relate to fatty acid oxidation, branched‐chain amino acid degradation and the immune system. Additionally, the AT depot comparison showed that the immune cell activation and T‐cell response appear up‐regulated in the Subq compared to the Epi AT depot. The miRNA prediction also suggested a modulation of T‐cell‐related biological process in Subq. In summary, the present study provides a unique resource for understanding the specific differences in gene expression that are driven by both excess GH action and AT depot location. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
21. The Effects of 20-kDa Human Placental GH in Male and Female GH-deficient Mice: An Improved Human GH?
- Author
-
List, Edward O, Berryman, Darlene E, Basu, Reetobrata, Buchman, Mathew, Funk, Kevin, Kulkarni, Prateek, Duran-Ortiz, Silvana, Qian, Yanrong, Jensen, Elizabeth A, Young, Jonathan A, Yildirim, Gozde, Yakar, Shoshana, and Kopchick, John J
- Published
- 2020
- Full Text
- View/download PDF
22. Lessons from growth hormone receptor gene-disrupted mice: are there benefits of endocrine defects?
- Author
-
Basu, Reetobrata, Yanrong Qian, and Kopchick, John J.
- Subjects
- *
ENDOCRINE diseases , *SOMATOTROPIN receptors , *HORMONE therapy , *HORMONE resistance , *LABORATORY mice , *LARON dwarfism - Abstract
Growth hormone (GH) is produced primarily by anterior pituitary somatotroph cells. Numerous acute human (h) GH treatment and long-term follow-up studies and extensive use of animal models of GH action have shaped the body of GH research over the past 70 years. Work on the GH receptor (R)-knockout (GHRKO) mice and results of studies on GH-resistant Laron Syndrome (LS) patients have helped define many physiological actions of GH including those dealing with metabolism, obesity, cancer, diabetes, cognition and aging/longevity. In this review, we have discussed several issues dealing with these biological effects of GH and attempt to answer the question of whether decreased GH action may be beneficial. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
23. Growth Hormone Upregulates Mediators of Melanoma Drug Efflux and Epithelial-to-Mesenchymal Transition In Vitro and In Vivo.
- Author
-
Qian, Yanrong, Basu, Reetobrata, Mathes, Samuel C., Arnett, Nathan A., Duran-Ortiz, Silvana, Funk, Kevin R., Brittain, Alison L., Kulkarni, Prateek, Terry, Joseph C., Davis, Emily, Singerman, Jordyn T., Henry, Brooke E., List, Edward O., Berryman, Darlene E., and Kopchick, John J.
- Subjects
- *
CELL proliferation , *ANIMAL experimentation , *BIOLOGICAL models , *CELL lines , *CELL receptors , *DRUG resistance in cancer cells , *MELANOMA , *MICE , *SOMATOMEDIN , *GENETIC markers , *HUMAN growth hormone , *IN vitro studies , *IN vivo studies , *EPITHELIAL-mesenchymal transition - Abstract
Simple Summary: Growth hormone (GH) action is strongly implicated in the progression and therapy resistance in several types of solid tumors which overexpress the GH receptor (GHR). The aim of our study was to characterize the effects of GH and its downstream effector insulin-like growth factor 1 (IGF-1) on melanoma using in vitro and in vivo models. We confirmed an IGF-1-independent role of elevated circulating GH in upregulating key mechanisms of therapy resistance and malignancy with analyses conducted at the molecular and cellular level. We identified that GH upregulates key mechanisms of therapy resistance and metastases in melanoma tumors in an IGF-1 dependent and independent manner by upregulating multidrug efflux pumps and EMT transcription factors. Our study reveals that GH action renders an intrinsic drug resistance phenotype to the melanoma tumors—a clinically crucial property of GH verifiable in other human cancers with GHR expression. Growth hormone (GH) and the GH receptor (GHR) are expressed in a wide range of malignant tumors including melanoma. However, the effect of GH/insulin-like growth factor (IGF) on melanoma in vivo has not yet been elucidated. Here we assessed the physical and molecular effects of GH on mouse melanoma B16-F10 and human melanoma SK-MEL-30 cells in vitro. We then corroborated these observations with syngeneic B16-F10 tumors in two mouse lines with different levels of GH/IGF: bovine GH transgenic mice (bGH; high GH, high IGF-1) and GHR gene-disrupted or knockout mice (GHRKO; high GH, low IGF-1). In vitro, GH treatment enhanced mouse and human melanoma cell growth, drug retention and cell invasion. While the in vivo tumor size was unaffected in both bGH and GHRKO mouse lines, multiple drug-efflux pumps were up regulated. This intrinsic capacity of therapy resistance appears to be GH dependent. Additionally, epithelial-to-mesenchymal transition (EMT) gene transcription markers were significantly upregulated in vivo supporting our current and recent in vitro observations. These syngeneic mouse melanoma models of differential GH/IGF action can be valuable tools in screening for therapeutic options where lowering GH/IGF-1 action is important. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
24. Growth Hormone Upregulates Melanocyte-Inducing Transcription Factor Expression and Activity via JAK2-STAT5 and SRC Signaling in GH Receptor-Positive Human Melanoma.
- Author
-
Basu, Reetobrata, Kulkarni, Prateek, Qian, Yanrong, Walsh, Christopher, Arora, Pranay, Davis, Emily, Duran-Ortiz, Silvana, Funk, Kevin, Ibarra, Diego, Kruse, Colin, Mathes, Samuel, McHugh, Todd, Brittain, Alison, Berryman, Darlene E., List, Edward O., Okada, Shigeru, and Kopchick, John J.
- Subjects
- *
PROTEIN-tyrosine kinase inhibitors , *ANIMAL experimentation , *CANCER chemotherapy , *CELL receptors , *CELLULAR signal transduction , *DRUG resistance , *EPITHELIAL cells , *GENE expression , *MELANOMA , *MICE , *TRANSCRIPTION factors , *HUMAN growth hormone , *IN vitro studies , *IN vivo studies , *THERAPEUTICS - Abstract
Growth hormone (GH) facilitates therapy resistance in the cancers of breast, colon, endometrium, and melanoma. The GH-stimulated pathways responsible for this resistance were identified as suppression of apoptosis, induction of epithelial-to-mesenchymal transition (EMT), and upregulated drug efflux by increased expression of ATP-binding cassette containing multidrug efflux pumps (ABC-transporters). In extremely drug-resistant melanoma, ABC-transporters have also been reported to mediate drug sequestration in intracellular melanosomes, thereby reducing drug efficacy. Melanocyte-inducing transcription factor (MITF) is the master regulator of melanocyte and melanoma cell fate as well as the melanosomal machinery. MITF targets such as the oncogene MET, as well as MITF-mediated processes such as resistance to radiation therapy, are both known to be upregulated by GH. Therefore, we chose to query the direct effects of GH on MITF expression and activity towards conferring chemoresistance in melanoma. Here, we demonstrate that GH significantly upregulates MITF as well as the MITF target genes following treatment with multiple anticancer drug treatments such as chemotherapy, BRAF-inhibitors, as well as tyrosine-kinase inhibitors. GH action also upregulated MITF-regulated processes such as melanogenesis and tyrosinase activity. Significant elevation in MITF and MITF target gene expression was also observed in mouse B16F10 melanoma cells and xenografts in bovine GH transgenic (bGH) mice compared to wild-type littermates. Through pathway inhibitor analysis we identified that both the JAK2-STAT5 and SRC activities were critical for the observed effects. Additionally, a retrospective analysis of gene expression data from GTEx, NCI60, CCLE, and TCGA databases corroborated our observed correlation of MITF function and GH action. Therefore, we present in vitro, in vivo, and in silico evidence which strongly implicates the GH–GHR axis in inducing chemoresistance in human melanoma by driving MITF-regulated and ABC-transporter-mediated drug clearance pathways. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
25. Common and uncommon mouse models of growth hormone deficiency.
- Author
-
List EO, Basu R, Berryman DE, Duran-Ortiz S, Martos-Moreno GÁ, and Kopchick JJ
- Abstract
Mouse models of growth hormone deficiency (GHD) have provided important tools for uncovering the various actions of GH. Nearly 100 years of research using these mouse lines has greatly enhanced our knowledge of the GH/IGF-1 axis. Some of the shared phenotypes of the five "common" mouse models of GHD include reduced body size, delayed sexual maturation, decreased fertility, reduced muscle mass, increased adiposity, and enhanced insulin sensitivity. Since these common mouse lines outlive their normal-sized littermates - and have protection from age-associated disease - they have become important fixtures in the aging field. On the other hand, the twelve "uncommon" mouse models of GHD described herein have tremendously divergent health outcomes ranging from beneficial aging phenotypes (similar to those described for the common models) to extremely detrimental features (such as improper development of the CNS, numerous sensory organ defects, and embryonic lethality). Moreover, advancements in next generation sequencing technologies have led to the identification of an expanding array of genes that are recognized as causative agents to numerous rare syndromes with concomitant GHD. Accordingly, this review provides researchers with a comprehensive up-to-date collection of the common and uncommon mouse models of GHD that have been used to study various aspects of physiology and metabolism associated with multiple forms of GHD. For each mouse line presented, the closest comparable human syndromes are discussed providing important parallels to the clinic., (© The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. See the journal About page for additional terms.)
- Published
- 2024
- Full Text
- View/download PDF
26. The effects of growth hormone on therapy resistance in cancer.
- Author
-
Basu R and Kopchick JJ
- Abstract
Pituitary derived and peripherally produced growth hormone (GH) is a crucial mediator of longitudinal growth, organ development, metabolic regulation with tissue specific, sex specific, and age-dependent effects. GH and its cognate receptor (GHR) are expressed in several forms of cancer and have been validated as an anti-cancer target through a large body of in vitro , in vivo and epidemiological analyses. However, the underlying molecular mechanisms of GH action in cancer prognosis and therapeutic response had been sparse until recently. This review assimilates the critical details of GH-GHR mediated therapy resistance across different cancer types, distilling the therapeutic implications based on our current understanding of these effects., Competing Interests: Conflicts of interest All authors declared that there are no conflicts of interest.
- Published
- 2019
- Full Text
- View/download PDF
27. MECHANISMS IN ENDOCRINOLOGY: Lessons from growth hormone receptor gene-disrupted mice: are there benefits of endocrine defects?
- Author
-
Basu R, Qian Y, and Kopchick JJ
- Subjects
- Animals, Endocrine System Diseases psychology, Humans, Laron Syndrome genetics, Laron Syndrome physiopathology, Longevity, Mice, Endocrine System Diseases genetics, Endocrine System Diseases physiopathology, Growth Hormone physiology, Human Growth Hormone physiology, Mice, Knockout genetics, Receptors, Somatotropin genetics
- Abstract
Growth hormone (GH) is produced primarily by anterior pituitary somatotroph cells. Numerous acute human (h) GH treatment and long-term follow-up studies and extensive use of animal models of GH action have shaped the body of GH research over the past 70 years. Work on the GH receptor (R)-knockout (GHRKO) mice and results of studies on GH-resistant Laron Syndrome (LS) patients have helped define many physiological actions of GH including those dealing with metabolism, obesity, cancer, diabetes, cognition and aging/longevity. In this review, we have discussed several issues dealing with these biological effects of GH and attempt to answer the question of whether decreased GH action may be beneficial., (© 2018 European Society of Endocrinology.)
- Published
- 2018
- Full Text
- View/download PDF
28. Targeting growth hormone receptor in human melanoma cells attenuates tumor progression and epithelial mesenchymal transition via suppression of multiple oncogenic pathways.
- Author
-
Basu R, Wu S, and Kopchick JJ
- Subjects
- Blotting, Western, Cell Line, Tumor, Disease Progression, Fluorescent Antibody Technique, Gene Knockdown Techniques, Human Growth Hormone metabolism, Humans, Melanoma metabolism, Polymerase Chain Reaction, Epithelial-Mesenchymal Transition physiology, Melanoma pathology, Receptors, Somatotropin metabolism, Signal Transduction physiology
- Abstract
Recent reports have confirmed highest levels of growth hormone (GH) receptor (GHR) transcripts in melanoma, one of the most aggressive forms of human cancer. Yet the mechanism of GH action in melanoma remains mostly unknown. Here, using human malignant melanoma cells, we examined the effects of GH excess or siRNA mediated GHR knock-down (GHRKD) on tumor proliferation, migration and invasion. GH promoted melanoma progression while GHRKD attenuated the same. Western blot analysis revealed drastic modulation of multiple oncogenic signaling pathways (JAK2, STAT1, STAT3, STAT5, AKT, mTOR, SRC and ERK1/2) following addition of GH or GHRKD. Further, we show that GH excess upregulates expression of markers of epithelial mesenchymal transition in human melanoma, while the effects were reversed by GHRKD. Interestingly, we observed consistent expression of GH transcript in the melanoma cells as well as marked modulation of the IGF receptors and binding proteins (IGF1R, IGF2R, IR, IGFBP2, IGFBP3) and the oncogenic HGF-MET mRNA, in response to excess GH or GHRKD. Our study thus identifies the mechanistic model of GH-GHR action in human melanoma and validates it as an important pharmacological target of intervention.
- Published
- 2017
- Full Text
- View/download PDF
29. Optimization of pyrrolamides as mycobacterial GyrB ATPase inhibitors: structure-activity relationship and in vivo efficacy in a mouse model of tuberculosis.
- Author
-
P SH, Solapure S, Mukherjee K, Nandi V, Waterson D, Shandil R, Balganesh M, Sambandamurthy VK, Raichurkar AK, Deshpande A, Ghosh A, Awasthy D, Shanbhag G, Sheikh G, McMiken H, Puttur J, Reddy J, Werngren J, Read J, Kumar M, R M, Chinnapattu M, Madhavapeddi P, Manjrekar P, Basu R, Gaonkar S, Sharma S, Hoffner S, Humnabadkar V, Subbulakshmi V, and Panduga V
- Subjects
- Animals, Cell Line, Humans, Mice, Mycobacterium tuberculosis drug effects, Structure-Activity Relationship, Antitubercular Agents pharmacology, Antitubercular Agents therapeutic use, Mycobacterium tuberculosis pathogenicity, Tuberculosis drug therapy
- Abstract
Moxifloxacin has shown excellent activity against drug-sensitive as well as drug-resistant tuberculosis (TB), thus confirming DNA gyrase as a clinically validated target for discovering novel anti-TB agents. We have identified novel inhibitors in the pyrrolamide class which kill Mycobacterium tuberculosis through inhibition of ATPase activity catalyzed by the GyrB domain of DNA gyrase. A homology model of the M. tuberculosis H37Rv GyrB domain was used for deciphering the structure-activity relationship and binding interactions of inhibitors with mycobacterial GyrB enzyme. Proposed binding interactions were later confirmed through cocrystal structure studies with the Mycobacterium smegmatis GyrB ATPase domain. The most potent compound in this series inhibited supercoiling activity of DNA gyrase with a 50% inhibitory concentration (IC50) of <5 nM, an MIC of 0.03 μg/ml against M. tuberculosis H37Rv, and an MIC90 of <0.25 μg/ml against 99 drug-resistant clinical isolates of M. tuberculosis. The frequency of isolating spontaneous resistant mutants was ∼10(-6) to 10(-8), and the point mutation mapped to the M. tuberculosis GyrB domain (Ser208 Ala), thus confirming its mode of action. The best compound tested for in vivo efficacy in the mouse model showed a 1.1-log reduction in lung CFU in the acute model and a 0.7-log reduction in the chronic model. This class of GyrB inhibitors could be developed as novel anti-TB agents.
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.